Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 7 Distribution of patients in subgroups by treatment with corresponding pCR rates

From: Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

   n (pCR)
   ddAT – Tamoxifen (n = 98) ddAT + Tamoxifen (n = 98)
ER+ HER2+ 11 (1) 10 (0)
  HER2- 46 (1) 42 (0)
  HER2 status missing 1 (0) 0 (0)
  Total 58 (2) 52 (0)
ER- HER2+ 12 (1) 13 (0)
  HER2- 28 (6) 33 (8)
  Total 40 (7) 46 (8)
Total   98 (9) 98 (8)
  1. ddAT, dose-dense Adriblastin (Doxorubicin) and Taxotere (Docetaxel); ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; pCR, pathological complete remission.